Gene expression profiling of differentiated thyroid neoplasms: Diagnostic and clinical implications

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6586-6597

  Chevillard, Sylvie ^a   Ugolin, Nicolas ^a   Vielh, Philippe ^b   Ory, Katherine ^a   Levalois, Céline ^a   Elliott, Danielle ^c   Clayman, Gary L ^c   El Naggar, Adel K ^c  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FOLLICULAR CARCINOMA; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID ADENOMA; THYROID CARCINOMA; TUMOR CLASSIFICATION;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADOLESCENT; ADULT; AGED; ALGORITHMS; CARCINOMA, PAPILLARY; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; THYROID NEOPLASMS;

EID: 5144226423     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0053     Document Type: Article

References (50)

1. Fagin JA. Perspective lesions learned from molecular genetic studies of thyroid cancer - insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 2002;143:2025-8.
2. Links TP, van Tol KM, Meerman GJ, deVries EG. Differentiated thyroid carcinoma: a polygenic disease. Thryoid 2001;11:1135-40.
3. Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic 1946 through 1970: initial manifestations pathologic findings, therapy, and outcome. Mayo Clin Proc 1991;66:11-22.
4. Wanebo HJ, Andrews W, Kaiser DL. Thyroid cancer: some basic considerations. CA Cancer J Clin 1983;33:87-97.
5. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-7.
6. Wiseman SM, Loree TR, Rigual NR, et al. Papillary thyroid cancer: high inter-(simple sequence repeat) genomic instability in a typical indolent cancer. Head Neck 2003;25:825-32.
7. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26:1016-23.
8. Garcia-Rostan G, Camp RK, Herrero A, Carcangiu M, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms down-regulation, aberrant nuclear expression, a CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001;158:987-96.
9. Masood S, Auguste LJ, Westerband A, Belluco C, Valderama E, Attie J. Differential oncogenic expression in thyroid follicular and Hurthle cell carcinomas. Am J Surg 1993;166:366-8.
10. Hoos A, Stojadinovic A, Singh B, et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 2002;160:175-83.
11. Frisk T, Kytola S, Wallin G, Zedenius J, Larsson C. Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. Genes Chromosomes Cancer 1999;25:349-53.
12. Takahashi M. Oncogenic activation of the ret protooncogene in thyroid cancer. Crit Rev Oncog 1995;6:35-46.
13. Yeh JJ, Marsh DJ, Zedenius J, et al. Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenoma and follicular thyroid carcinomas develop along distinct neoplastic pathways. Gene chromosomes Cancer 1999;26:322-8.
14. Rodrigues-Serpa A, Catarino A, Soares J. Loss of heterozygosity in follicular and papillary thyroid carcinomas. Cancer Genet Cytogenet 2003;141:26-31.
15. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001;98:15044-9.
16. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003;9:68-75.
17. Barden CB, Shister KW, Zhu B, et al. 3rd, Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003;9:1792-800.
18. Soares MB, Bonaldo MF, Jelene P, Su L, Lawton, L, Efstratiadis A. Construction and characterization of a normalized cDNA library. Proc Natl Acad Sci USA, 1994;91:9228-32.
19. Lee ML, Kuo FC, Whitmore GA, Sklar J. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc Natl Acad Sci USA 2000:97;9834-9.
20. Schulze A, Downward J. Analysis of gene expression by microarrays: cell biologist's gold mine or minefield? J Cell Sci 2000;113;4151-6.
21. Tu Y, Stolovitzky G, Klein U. Quantitative noise analysis for gene expression microarray experiments. Proc Natl Acad Sci USA 2002;99:14031-6.
22. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 2001;29:2549-57.
23. Ory K, Lebeau J, Levalois C, et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat 2001;68:187-98.
24. Bishay K, Ory K, Olivier MF, Lebeau J, Levalois C, Chevillard S. DNA damage-related RNA expression to assess individual sensitivity to ionizing radiation. Carcinogenesis 2001;22:1179-83.
25. Ishibashi T, Bottaro DP, Michieli P, Kelley CA, Aaronson SA. A novel dual specificity phosphatase induced by serum stimulation and heat shock. J Biol Chem 1994;269:29897-902.
26. Rigolet M, Rich T, Gross-Morand MS, Molina-Gomes D, Viegas-Pequignot E, Junien C. cDNA cloning, tissue distribution and chromosomal localization of the human ID4 gene. DNA Res 1998;5:309-13.
27. Markert JM, Fuller CM, Gillespie GY, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001;5:21-33.
28. Line A, Stengrevics A, Slucka Z, Li G, Jankevics E, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer 2002;86:1824-30.
29. Jones MB, Michener CM, Blanchette JO, et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 2003;9:44-51.
30. Manzano RG, Montuenga LM, Dayton M, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002;21:4435-47.
31. Sandrini F, Matyakhina L, Sarlis NJ, et al. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer 2002;35:182-92.
32. Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 2001;25:302-6.
33. Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Pol J Pathol 2002;53:129-32.
34. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162:1807-15.
35. Carmon L, Bobilev-Priel I, Breener B, et al. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J Clin Investig 2002;110:453-62.
36. Kondo T, Raff M. The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J 2000;19:1998-2007.
37. Seol W, Hanstein B, Brown M, Moore DD. Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol Endocrinol 1998;12:1551-7.
38. Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Nad Acad Sci USA 1993;90:5648-52.
39. Gimm O, Dziema H, Brown J, et al. Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. Int J Cancer 2001;92:70-4.
40. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. An alternative pathway for gene regulation by Myc. EMBO J 1997;16:5672-86.
41. Shintani S, Mihara M, Terakado N, et al. Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res 2001;7:2776-82.
42. Okabe H, Satoh S, Furukawa Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003;63:3043-8.
43. Kim JY, Cho H, Rhee BD, Kim HY. Expression of CD44 and cyclin D1 in fine needle aspiration cytology of papillary thyroid carcinoma. Acta Cytol 2002;46:679-83.
44. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002;87:1814-8.
45. Hirota S, Nakajima Y, Yoshimine T, et al. Expression of bone-related protein messenger RNA in human meningiomas: possible involvement of osteopontin in development of psammoma bodies. J Neuropathol Exp Neurol 1995;54:698-703.
46. Maki M, Hirota S, Kaneko Y, Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int 2000;50:531-5.
47. Tunio GM, Hirota S, Nomura S, Kitamura Y. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 1998;122:1087-90.
48. Carmeci C, Thompson DA, Kuang WW, Lightdale N, Furthmar H, Weigel RJ. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype. Surgery (St Louis) 1998;124:211-7.
49. Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999;5:237-41.
50. Lloyd RV, Johnson TL, Blaivas M, Sisson JC, Wiksibm BS. Detection of HLA-DR antigens in paraffin-embedded thyroid epithelial cells with a monoclonal antibody. Am J Pathol 1985;120:106-11.